Seroprevalence of Antibodies against SARS-CoV-2 in Children with Juvenile Idiopathic Arthritis a Case-Control Study

Opoka-Winiarska, Violetta; Grywalska, Ewelina; Korona-Głowniak, Izabela; Matuska, Katarzyna; Malm, Anna; Roliński, Jacek

doi:10.3390/jcm10081771

Cited by 3 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our previous study conducted during the first wave of the COVID-19 pandemic (from 1 June to 30 September 2020), with a confirmed number of cases from 362 to 1405 per day/39.3 million inhabitants, the prevalence of anti-SARS-CoV-2 antibodies in children with JIA was assessed [ 4 , 7 ]. At that time, lower seropositivity in children with JIA (12.9% positive in at least one of the antibodies IgA or IgG) and a slightly higher seropositivity in healthy children was noted [ 4 ].…”

Section: Discussionmentioning

confidence: 99%

“…Similar studies in children with rheumatic diseases have been conducted in other countries [ 8 , 9 , 10 ]. In a study conducted in Turkey from March 2020 to August 2020 [ 8 ], exactly in the period of our first study [ 4 ], 149 children asymptomatic for COVID-19 (43 healthy children, 42 with JIA, and 64 with other rheumatic diseases) were included. The proportion positive for anti-SARS-CoV-2 IgA or IgG was 12.75% children, including 18.6% healthy children and 11.9% diagnosed with JIA, but those differences were not statistically significant.…”

Section: Discussionmentioning

confidence: 99%

“…The course of COVID-19 in children with rheumatic diseases is carefully monitored [ 3 ]. Our recently published study showed no unequivocal correlation between the presence of SARS-CoV-2 antibodies and juvenile idiopathic arthritis (JIA) activity [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Programmed Cell Death Protein-1 Upregulation in Response to SARS-CoV-2 in Juvenile Idiopathic Arthritis: A Case-Control Study

Opoka-Winiarska

Grywalska

Korona-Głowniak

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

Currently, data regarding the impact of COVID-19 disease (caused by SARS-CoV-2) on patients with childhood rheumatic diseases are significantly limited. To assess the possible connection, we measured levels of IgA and IgG anti-SARS-CoV-2 antibodies in children with juvenile idiopathic arthritis (JIA) and a control group during the pandemic, prior to the introduction of anti-COVID-19 vaccination. We assessed levels of PD-1 suppressive molecule and inflammatory markers in patients and correlated those results with serological response to SARS-CoV-2. In JIA patients, the activity of the disease was assessed using the Juvenile Arthritis Disease Activity Score 71 (JADAS 71) scale. The study consisted of 96 children, 65 diagnosed with JIA, treated with antirheumatic drugs, and 31 healthy volunteers. In patients with JIA, significantly higher levels of SARS-CoV-2 antibodies in the IgA and IgG were demonstrated compared to the control group. We also found significantly higher serum PD-1 levels in JIA patients and control volunteers who were seropositive for SARS-CoV-2 IgA or IgG antibodies compared to those who were seronegative. The humoral immune response to SARS-CoV-2 infection is associated with the persistent upregulation of PD-1 expression in both JIA patients and healthy children. The clinical significance of the detected disorder requires further careful observation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Programmed Cell Death Protein-1 Upregulation in Response to SARS-CoV-2 in Juvenile Idiopathic Arthritis: A Case-Control Study

Opoka-Winiarska

Grywalska

Korona-Głowniak

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“… [ 76 ] Poland Case–Control Study 12(2–18) JIA 62 - JIA patients do not exhibit a higher seroprevalence of anti-SARS-CoV-2 antibodies than healthy individuals. [ 82 ] Turkey Single-center, retrospective study 12 JIA, FMF, systemic autoinflammatory diseases 87(37–50) - Children with rheumatic diseases do not have a higher chance of developing severe COVID-19. - The disease's severity is unaffected by biological treatment.…”

Section: Rheumatic Diseasesmentioning

confidence: 99%

Coronavirus disease 2019 (COVID-19) in pediatric patients with autoimmune disorders

2023

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) infection in pediatric patients with autoimmune disorders is an area of particular concern since autoimmune diseases can increase the risk of complications from the virus. However, as the infection rates were significantly higher in adults compared to children, this at-risk group of children was relatively underrepresented in COVID-19 research. The underlying inflammatory basis of autoimmune diseases and medications that affect the immune system, such as corticosteroids, could increase the risk of severe infection in this group of patients. COVID-19 could reportedly lead to a variety of alterations in the immune system. These alterations are plausibly dependent on the underlying immune-mediated diseases or prior use of immunomodulatory drugs. Patients administrating immunomodulatory agents, especially those with severe immune system dysregulation, can experience severe symptoms of COVID-19. Nonetheless, receiving immunosuppressive medications can benefit patients by preventing cytokine storm syndromes and lung tissue damage, threatening outcomes of COVID-19. Conclusion: In this review, we sought to evaluate the currently available literature on the impact of autoimmune disease and its related therapeutic approaches on the COVID-19 infection course of disease in children and reflect on the gaps in the evidence and the need for further research in this field. What is Known: • The majority of children infected with COVID-19 demonstrate mild to moderate clinical manifestations compared to adults, whereas those children with pre-existing autoimmune conditions are at a greater risk for severe symptoms. •There is currently limited understanding of the pathophysiology and clinical outcomes of COVID-19 in pediatric patients with autoimmune disorders due to scattered reports and inadequate evidence. What is New: • Generally, children with autoimmune disorders have more unfavorable outcomes than healthy children; yet, the severity is not extreme, and is highly dependent on their autoimmune disease type and severity, as well as the medication they are taking.

show abstract

“…These findings support that patients in whom JIA is stably controlled by biologics without/with low‐dose prednisolone show favorable outcomes. Opoka‐Winiarska et al 8 reported that eight JIA patients on immunosuppressive therapy with no history of infection had anti‐SARS‐CoV‐2 antibodies, although 62 JIA patients did not have a higher seroprevalence of anti‐SARS‐CoV‐2 antibodies than 32 healthy children. In this setting, a more asymptomatic or less symptomatic infection of SARS‐CoV‐2 may occur in pediatric patients with RMDs than we expected.…”

Section: Case 1 2 3 4 5 6mentioning

confidence: 99%

Optimal biologics for juvenile idiopathic arthritis in an infection with SARS‐CoV‐2 α‐variant

Adachi

Sonoda

Ishimura

et al. 2021

Pediatric Allergy Immunology

View full text Add to dashboard Cite

Seroprevalence of Antibodies against SARS-CoV-2 in Children with Juvenile Idiopathic Arthritis a Case-Control Study

Cited by 3 publications

References 30 publications

Programmed Cell Death Protein-1 Upregulation in Response to SARS-CoV-2 in Juvenile Idiopathic Arthritis: A Case-Control Study

Programmed Cell Death Protein-1 Upregulation in Response to SARS-CoV-2 in Juvenile Idiopathic Arthritis: A Case-Control Study

Coronavirus disease 2019 (COVID-19) in pediatric patients with autoimmune disorders

Optimal biologics for juvenile idiopathic arthritis in an infection with SARS‐CoV‐2 α‐variant

Contact Info

Product

Resources

About